Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2
Список исп. литературыСкрыть список 1. Дробижев М.Ю. Селективные ингибиторы обратного захвата серотонина и норадреналина: возможно ли сочетание эффективности и безопасности? Психиатрия и психофармакотерапия. 2004; 6 (5): 248–50. / Drobizhev M.Iu. Selektivnye ingibitory obratnogo zakhvata serotonina i noradrenalina: vozmozhno li sochetanie effektivnosti i bezopasnosti? Psychiatry and Psychopharmacotherapy. 2004; 6 (5): 248–50. [in Russian] 2. Cultural Sociology of Mental Illness: An A-to-Z Guide (ed. A.T. Scull). Thousand Oaks: SAGE Publications 2014. 3. Marshall E, Stirling GS, Tait AC et al. The effect of iproniazid and imipramine on the blood platelet serotonin in man. Br J Pharmacol Chemother 1960; 15: 35–41. 4. Coppen A, Shaw DM, Farrell JP. Potentiation of the antidepressive effect of a monoamine-oxidase inhibitor by tryptophan. Lancet 1963; 1 (7272): 79–81. 5. Van Praag HM, Leijnse B. Die Bedeutung der Psychopharmakologie für die klinische Psychiatrie. Systematik als notwendinger Ausgangspunkt. Nervenartzt 1964; 34: 530–7. 6. Carlsson A, Fuxe K, Ungerstedt U. The effect of imipramine on central 5-hydroxytryptamine neurons. J Pharmacy Pharmacol 1968; 20 (2): 150–1. 7. Ashcroft GW, Crawford TBB, Eccleston D et al. 5-hydroxy-indole compounds in the cerebrospinal fluid of patients with psychiatric or neurological disease. Lancet 1966; 2 (7472): 1049 52. 8. Shaw DM, Camps FE, Eccleston EG. 5-hydroxytryptamine in the hind-brain of depressive suicides. Br J Psychiatr 1967; 113 (505): 1407–11. 9. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965; 122 (5): 509–22. 10. Schildkraut JJ, Schanberg SM, Breese GR et al. Norepinephrine metabolism and drugs used in the affective disorders: a possible mechanism of action. Am J Psychiatry 1967; 124 (5): 600–8. 11. Wong DT, Horng JS, Fuller RW. Kinetics of serotonin accumulation into synaptosomes of rat brain – effects of amphetamine and chloroamphetamines. Biochem Pharmacol 1973; 22 (3): 311–22. 12. Fuller RW, Perry KW, Molloy BB. Effect of an uptake inhibitor on serotonin metabolism in rat brain: studies with 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine (Lilly 110140). Life Sci 1974; 15 (6): 1161–71. 13. Wong DT, Horng JS, Bymaster FP et al. A selective inhibitor of serotonin uptake: Lilly 110140, 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine. Life Sci 1974; 15 (3): 471–9. 14. Ross SB, Ogren SO, Renyi AL. (Z)-dimethylamino-1-(4-bromophenyl)-1-(3-pyridyl) propene (h 102/09), a new selective inhibitor of the neuronal 5-hydroxytryptamine uptake. Acta Pharmacologica Toxicologica (Copenh) 1976; 39 (2): 152–66. 15. Berntsson PB, Carlsson PAE, Corrodi HR. Composés utiles en tant qu’agents anti-dépressifs, et procédé pour leur préparation. Belg Pat 1972; 781: 105. 16. Wong DT, Bymaster FP, Engleman EA. Prozac (Fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci 1995; 57 (5): 411–41. 17. Lieberman JA. History of the use of antidepressants in primary care. J Clin Psychiatry 2003; 5 (Suppl. 7): 6–10. 18. Carlsson A, Wong DT. A note on the discovery of selective serotonin reuptake inhibitors. Life Sci 1997; 61 (12): 1203. 19. Nilsson BS. Adverse reactions in connection with zimeldine treatment: a review. Acta Psychiatrica Scandinavica 1983; 68 (Suppl. 308): 115–9. 20. Bengtsson BO, Wiholm BE, Myrhed M et al. Adverse experiences during treatment with zimeldine on special licence in Sweden. Int Clin Psychopharmacol 1994; 9 (1): 55–61. 21. Le Fur G, Uzan A. Effect of 4-(3-indolyl-alkyl) piperidine derivatives on uptake and release of noradrenaline, dopamine and 5-hydroxytryptamine in rat brain synaptosomes, rat heart and human blood platelets. Biochem Pharmacol1977; 26 (6): 497–503. 22. Healey D. Let them eat Prozac: the unhealthy relationship between the pharmaceutical industry and depression. Medicine, Culture, and History. New York: New York University Press, 2004. 23. Meltzer HY, Young M, Metz J et al. Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant. J Neur Transmission 1979; 45 (2): 165–75. 24. Carlsson A. The discovery of the SSRIs: A milestone in neuropsychopharmacology and rational drug design. In: S.C.Stanford Selective Serotonin Reuptake Inhibitors (SSRIs): Past, Present and Future. Austin: R.G.Landes Company, 1999. 25. Danish University Antidepressant Group. Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology (Berl) 1986; 90 (1): 131–8. 26. Danish Universities Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1990; 18 (4): 289–99. 27. Lundbeck AS. Annual report 2000; p. 10–11, 13, 28, 30–2. 28. Dapoxetine: LY 210448. Drugs RD 2005; 6 (5): 307–11. 29. Salonia A, Rocchini L, Sacca' A et al. Acceptance of and discontinuation rate from paroxetine treatment in patients with lifelong premature ejaculation. J Sex Med 2009; 6 (10): 2868–77. 30. Schatzberg AF, Blier P, Culpepper L et al. An overview of vortioxetine. J Clin Psychiatry 2014; 75 (12): 1411–8. 31. Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord 1998; 51 (3): 215–35. 32. Балдессарини Р. Медикаментозное лечение депрессии и тревожных расстройств. В кн.: Клиническая фармакология по Гудману и Гилману (пер. с англ.). М.: Практика, 2006; с. 350–82. / Baldessarini R. Medikamentoznoe lechenie depressii i trevozhnykh rasstroistv. V kn.: Klinicheskaia farmakologiia po Gudmanu i Gilmanu (per. s angl.). M.: Praktika, 2006; s. 350–82. [in Russian] 33. Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications (4th ed). New York: Cambrigde University Press, 2013. 34. Lee BH. Kim YK. The roles of BDNF in the pathophysiology of major depression and in antidepressant treatment. Psychiatr Investig 2010; 7 (4): 231–5. 35. Siever LJ, Davis KL. Overview: toward dysregulation hypothesis of depression. Am J Psychiatry 1985; 142 (9): 1017–31. 36. Быков Ю.В., Беккер Р.А., Резников М.К. Депрессии и резистентность. М.: РИОР; ИНФРА-М, 2013. / Bykov Iu.V., Bekker R.A., Reznikov M.K. Depressii i rezistentnost'. M.: RIOR; INFRA-M, 2013. [in Russian] 37. Шацберг А.Ф., Коул Д.О., ДеБаттиста Ч. Руководство по клинической психофармакологии. Пер. с англ. Под ред. А.Б.Смулевич, С.В.Иванов. М.: МЕДпресс-информ, 2013. / Shatsberg A.F., Koul D.O., DeBattista Ch. Rukovodstvo po klinicheskoi psikhofarmakologii. Per. s angl. Pod red. A.B.Smulevich, S.V.Ivanov. M.: MEDpress-inform, 2013. [in Russian] 38. Попов Ю.В., Вид В.Д. Современная клиническая психиатрия. М.: Экспертное бюро-М, 1997. / Popov Iu.V., Vid V.D. Sovremennaia klinicheskaia psikhiatriia. M.: Ekspertnoe biuro-M, 1997. [in Russian] 39. Kaplan HI, Sadock BJ. Клиническая психиатрия. Пер. с англ., Под ред. Т.Б.Дмитриева. М.: ГЭОТАР-Медицина, 1998. / Kaplan HI, Sadock BJ. Klinicheskaia psikhiatriia. Per. s angl. Pod red. T.B.Dmitrieva. M.: GEOTAR-Meditsina, 1998 [in Russian] 40. Roose SP, Glassman AH, Attia E et al. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry 1994; 151 (12): 1735–9. 41. Яничак Ф.Дж., Дэвис Дж.М., Прескорн Ш.Х. и др. Принципы и практика психофармакотерапии. Пер. с англ. Киев: Ника-Центр, 1999. / Ianichak F.Dzh., Devis Dzh.M., Preskorn Sh.Kh. i dr. Printsipy i praktika psikhofarmakoterapii. Per. s angl. Kiev: Nika-Tsentr, 1999. [in Russian] 42. Арана Дж., Розенбаум Дж. Фармакотерапия психических расстройств. Пер. с англ. Под ред. С.Н.Мосолов. М.: БИНОМ, 2004. / Arana Dzh., Rozenbaum Dzh. Farmakoterapiia psikhicheskikh rasstroistv. Per. s angl., red. S.N.Mosolov. M.: BINOM, 2004. [in Russian] 43. Bazire S. Psychotropic drug directory 2003/04. Salisbury: Fivepin Publisshing, 2003. 44. Морозов П.В. Милнаципран – новые перспективы в терапии депрессивных расстройств. Психиатрия и психофармакотерапия. 2000; 2 (2): 57–9. / Morozov P.V. Milnatsipran – novye perspektivy v terapii depressivnykh rasstroistv. Psychiatry and Psychopharmacotherapy. 2000; 2 (2): 57–9. [in Russian] 45. Millan M.J. Препараты с двойным и тройным механизмом действия для лечения ядерных и коморбидных проявлений большой депрессии: новые концепции, новые препараты. Психиатрия и психофармакотерапия. 2009; 11 (3): 4–20. / Millan M.J. Preparaty s dvoinym i troinym mekhanizmom deistviia dlia lecheniia iadernykh i komorbidnykh proiavlenii bol'shoi depressii: novye kontseptsii, novye preparaty. Psychiatry and Psychopharmacotherapy. 2009; 11 (3): 4–20. [in Russian] 46. Смулевич А.Б., Морозова М.А. Антидепрессанты. В кн.: Руководство по психиатрии. Т. 1. Под ред. А.С.Тиганов, А.В.Снежневский, Д.Д.Орловская. М.: Медицина, 1999; с. 265–8. / Smulevich A.B., Morozova M.A. Antidepressanty. V kn.: Rukovodstvo po psikhiatrii. T. 1. Pod red. A.S.Tiganov, A.V.Snezhnevskii, D.D.Orlovskaia. M.: Meditsina, 1999; s. 265–8. [in Russian] 47. Kornstein SG, Schatzberg AF, Thase ME et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry 2000; 157 (9): 1445–2. 48. Краснов В.Н. Современные подходы к терапии депрессий. Рус. мед. журн. 2002; 10 (12–13): 553–5. / Krasnov V.N. Sovremennye podkhody k terapii depressii. Rus. med. zhurn. 2002; 10 (12–13): 553–5. [in Russian] 49. Смулевич А.Б. Психические расстройства в клинической практике. М.: МЕДпресс-информ, 2011. / Smulevich A.B. Psikhicheskie rasstroistva v klinicheskoi praktike. M.: MEDpress-inform, 2011. [in Russian] 50. Психиатрия. Национальное руководство (краткое изд.). Аффективные расстройства. Под ред. Т.Б.Дмитриева, В.Н.Краснова, Н.Г.Незнанова и др. М.: ГЭОТАР-Медиа, 2012. / Psikhiatriia. Natsional'noe rukovodstvo (kratkoe izd.). Affektivnye rasstroistva. Pod red. T.B.Dmitrieva, V.N.Krasnovа, N.G.Neznanovа i dr. M.: GEOTAR-Media, 2012. [in Russian] 51. Anderson IM. SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depression Anxiety 1998; 7 (Suppl. 1): 11–7. 52. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000; 58 (1): 19–36. 53. Ansseau M, Papart P, Troisfontaines B et al. Controlled comparison of milnacipran and fluoxetine in major depression. Psychopharmacology (Berl) 1994; 114 (1): 131–7. 54. Guelfi JD, Ansseau M, Corruble E et al. A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients. Int Clin Psychopharmacol 1998; 13 (3): 121–8. 55. Clerc G. Milnacipran/Fluvoxamine Study Group. Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine. Int Clin Psychopharmacol 2001; 16 (3): 145–51. 56. Morishita S, Arita S. Differential effects of fluvoxamine, paroxetine and milnacipran for depression, especially with regard to age. Hum Psychopharmacol 2004; 19 (6): 405–8. 57. Lee MS, Ham BJ, Kee BS et al. Comparison of efficacy and safety of milnacipran and fluoxetine in Korean patients with major depression. Curr Med Res Opin 2005; 21 (9): 1369–75. 58. Eckert L, Lançon C. Duloxetine compared with fluoxetine and venlafaxine: use of meta-regression analysis for indirect comparisons. BMC Psychiatry 2006; 6: 30. 59. Cipriani A, Furukawa TA, Salanti G et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009; 373 (9665): 746–58. 60. Freemantle N, Anderson I, Young P. Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs. Br J Psychiatr 2000; 177: 292–302. 61. Turner EH, Matthews AM, Linardatos E et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008; 358 (3): 252–60. 62. Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatr 2001; 50 (5): 345–50. 63. Незнанов Н.Г., Борцов А.В. Новое качество терапии расстройств тревожно-депрессивного спектра – эсциталопрам. Журн. неврологии и психиатрии им. С.С.Корсакова. 2005; 105 (2): 79–84. / Neznanov N.G., Bortsov A.V. Novoe kachestvo terapii rasstroistv trevozhno-depressivnogo spektra – estsitalopram. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2005; 105 (2): 79–84. [in Russian] 64. Изнак А.Ф., Поздеева Е.А., Изнак Е.В. «Чистые» стереоизомеры – новое направление повышения эффективности антидепрессантов (обзор литературы). Обозрение психиатрии и мед. психологии. 2008; 1: 8–13. / Iznak A.F., Pozdeeva E.A., Iznak E.V. «Chistye» stereoizomery – novoe napravlenie povysheniia effektivnosti antidepressantov (obzor literatury). Obozrenie psikhiatrii i med. psikhologii. 2008; 1: 8–13. [in Russian] 65. Lane RM, Baker GB. Chirality and drugs used in psychiatry: nice to know or need to know? Cell Mol Neurobiol 1999; 19 (3): 355–72. 66. Auquier P, Robitail S, Llorca PM et al. Comparison of escitalopram and citalopram efficacy: A meta-analysis. Int J Psychiatr Clin Pract 2003; 7 (4): 259–68. 67. Brown WA, Harrison W. Are patients who are intolerant to one SSRI intolerant to another? Psychopharmacol Bull 1992; 28 (3): 253–6. 68. Thase ME, Blomgren SL, Birkett MA et al. Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. J Clin Psychiatry 1997; 58 (1): 16–21. 69. Thase ME, Feighner JP, Lydiard RB. Citalopram treatment of fluoxetine nonresponders. J Clini Psychiatry 2001; 62 (9): 683–7. 70. Rush AJ, Trivedi MH, Wisniewski SR et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006; 354 (12): 1231–42. 71. Antidepressants, selective serotonin reuptake inhibitors (SSRI). Therapeutic class review (TRC). Cincinnati: Provider Synergies, LLC, 2013.